Answers are grounded in this paper and cite their sources.
Retrospective assessment reveals reduced intraocular pressure and medication use in severe glaucoma patients, indicating potential efficacy.
Purpose: To evaluate the efficacy and safety of ab-interno canaloplasty combined with microstent implantation in patients with severe glaucoma. Patients and Methods: This retrospective study included patients with severe glaucoma (mean age 74.6± 8.7 years), predominantly primary open-angle (90%). All eyes underwent combined ab-interno canaloplasty using the iTrack (Nova Eye Medical) with concurrent Hydrus Microstent (Alcon) implantation during cataract surgery. The primary outcome measures were intraocular pressure (IOP), number of glaucoma medications, visual field mean deviation (VFMD), postoperative complications. Results: Sixty-nine eyes of 56 patients were followed for mean 27.9± 13.8 months. Mean IOP decreased from 17.8± 6.3 at baseline to 15.5± 4.7 mmHg at last follow-up (p=0.012), and mean number of medications decreased by 47%, from 2.10± 1.1 to 1.12± 1.2 (p< 0.001). Medication-free eyes increased from 7% at baseline to 43% at last follow-up. Among eyes that were on 3 and 4 medications preoperatively (n=17; n=7), the number of medications significantly decreased by 53% (p< 0.001) and 57% (p=0.002) at last follow-up, while IOP remained stable. Eyes with baseline IOP > 18 mmHg (n=21) experienced a significant mean IOP reduction of 9.8 mmHg (from 24.8± 6.7 to 15.0± 4.6 mmHg; − 40%, p< 0.001). No intraoperative or postoperative complications were reported; 6 eyes (9%) required additional glaucoma procedures during follow-up. Conclusion: Combining ab-interno canaloplasty with Hydrus Microstent implantation during cataract surgery resulted in modest but sustained reductions in intraocular pressure and glaucoma medication burden, with a favorable safety profile. However, postoperative IOP frequently remained above levels required for very low target pressures. These findings suggest that this mixed MIGS approach may be considered in carefully selected patients but should not be viewed as a substitute for traditional filtering surgery in advanced disease.
No takes yet. Share an insight, caveat, or question.
Justin Spaulding (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: